Pelareorep + Checkpoint Inhibitor

About Oncolytics Biotech

Oncolytics Biotech is advancing pelareorep, a unique oncolytic virus that selectively replicates in cancer cells and stimulates a systemic anti-tumor immune response. The company's strategy is centered on GI cancers, where it has generated compelling clinical data, including a 62% objective response rate in first-line mPDAC and more than doubled survival benchmarks in KRAS-mutant mCRC. With a seasoned leadership team and a clear focus on registration-enabling studies, Oncolytics aims to bring a novel, tolerable immunotherapy to patients facing devastating GI malignancies.

Therapeutic Areas